The Evolution of Cytopathology Reporting: Standardization, Precision, and Future Directions

Fernando Schmitt[*]

RISE-Health, Department of Pathology, Medical Faculty of the University of Porto, Porto, Portugal

Cytopathology has undergone a significant transformation in recent decades, driven by advances in diagnostic techniques, molecular pathology, and the need for standardized communication between pathologists and clinicians. The introduction and continuous refinement of structured reporting systems have provided a critical framework for ensuring diagnostic accuracy, reproducibility, and optimal patient management. This special issue of the *Journal of Clinical and Translational Pathology* brings together a series of articles highlighting major reporting systems in cytopathology, demonstrating their evolution, impact, and future directions.

Standardized reporting systems address several key challenges in cytopathology. They provide clear diagnostic categories, define the risk of malignancy (ROM) for each category, and offer management recommendations.[1] These frameworks are essential for maintaining consistency across institutions and pathologists, facilitating interdisciplinary communication, and supporting clinical decision-making. Among the reporting systems discussed in this issue are The Paris System for Urinary Cytology, The Bethesda System for Reporting Cervical and Thyroid Cytopathology, The Yokohama System for Breast Cytology, The Milan System for Salivary Gland Cytopathology, and the emerging World Health Organization (WHO)-International Academy of Cytology (IAC) universal reporting systems for multiple organ sites.

The WHO-IAC Reporting Systems represent a significant step toward global standardization in cytopathology.[1] By providing a universal lexicon for cytopathology, these systems bridge diagnostic gaps across regions with varying levels of resources. The WHO-IAC systems have already been implemented in key areas such as lung,[2,3] pancreaticobiliary,[4,5] lymph node,[6] and soft tissue cytopathology,[7] and are currently expanding into liver, breast, kidney and adrenal, and head and neck cytopathology. Their structured approach ensures consistency, enhances diagnostic reproducibility, and facilitates clinical decision-making in diverse healthcare settings.

The pioneering system of systematic cytopathology reporting was the Bethesda System for Reporting Cervical Cytology, discussed in the article by Wang *et al.*,[8] which has played a pivotal role in the early detection and management of cervical cancer. Since its inception in 1988, the Bethesda System has standardized cervical cytology reporting, ensuring clear communication of findings and appropriate clinical follow-up. Recent updates incorporate advancements in HPV testing and reflect evolving guidelines for cervical cancer screening. This system was followed by the Bethesda System for Reporting Thyroid Cytopathology, as reviewed by Min Han and Fang Fan.[9] This system has undergone multiple revisions to refine risk stratification and incorporate molecular diagnostics. The third edition, recently published, introduces key updates in histologic terminology and risk assessment. These changes underscore the dynamic nature of cytopathology and the continuous need to integrate emerging scientific knowledge into practice.[10] While the Bethesda System established the paradigm for organ-specific standardization, subsequent systems like the Paris System addressed unique diagnostic challenges in their respective fields, demonstrating how cytopathology reporting continues to evolve to meet clinical needs.

The Paris System for Reporting Urinary Cytology (TPS), reviewed by Fei Chen and Xiaoqi Lin, has evolved significantly since its introduction in 2016 and subsequent update in 2022.[11] By emphasizing high specificity in detecting high-grade urothelial carcinoma while reducing unnecessary indeterminate diagnoses, this system has improved diagnostic accuracy and clinical utility. The review provides a comprehensive update on TPS 2.0, including its impact on clinical practice and the role of molecular testing in urinary cytology.[12]

Similarly, breast cytology has benefited from standardized reporting through The Yokohama System, which stratifies breast lesions into five diagnostic categories with defined ROM and management strategies.[13] The article by Yu *et al.*[14] emphasizes the significance of this system in improving diagnostic confidence and reducing unnecessary interventions. Although breast cytology is being replaced by core-needle biopsy in several scenarios, this methodology is still used in many countries and continues to be very helpful, as demonstrated in our practice.[15] At this moment, the WHO is preparing a reporting system that will replace the Yokohama System but maintain its structure.

The Milan System for Reporting Salivary Gland Cytopathology has similarly provided much-needed clarity in classifying salivary gland lesions, as explored in the review by Xi

[*]**Correspondence to:** Fernando Schmitt, RISE-Health, Department of Pathology, Medical Faculty of the University of Porto, Porto (4200-319), Portugal. ORCID: https://orcid.org/0000-0003-1006-6946. Tel: +351-220426534, Fax: +351-220426534, E-mail: fschmitt@med.up.pt

Wang and He Wang.[16] Since its introduction, it has enhanced risk stratification, facilitating better clinical decision-making and surgical planning. Updates to this system continue to refine diagnostic criteria and incorporate emerging molecular markers.[17]

Other critical reporting systems covered in this issue include The International System for Reporting Serous Fluid Cytopathology, which standardizes the evaluation of effusion specimens.[18] When handled and examined correctly, effusion specimens can enable fast and reliable diagnoses, with a profound impact on clinical management.[19] Building on the foundation of other cytology reporting nomenclature systems, the IAC and the American Society of Cytopathology assembled a team of experts to develop a standardized reporting system for serous effusion cytology, called the International System for Reporting Serous Fluid Cytology (TIS). Grounded in the latest research and expert consensus, TIS aims to provide a framework to minimize reporting variability.[20] To maintain its viability and flexibility, it is essential to periodically review and update the language, criteria, and impact of the system. In line with this, the system is currently under review for the launch of a second edition of TIS.

The two already well-established WHO Reporting Systems for Lung and Pancreaticobiliary Cytopathology are also reviewed in this special issue.[2–5] The concept and development of these WHO reporting systems have been almost universally positively received and supported by the cytopathology community, and they are generating a lot of research in an attempt to establish more refined ROM rates and their implications for patient management.

The recently launched WHO Reporting System for Lymph Node, Spleen, and Thymus Cytopathology marks a crucial advancement in the classification and risk stratification of lymphoid and hematopoietic disorders.[6] Fine-needle aspiration biopsy has proven to be a highly effective diagnostic tool for lymph node disorders, offering minimal invasiveness, rapid turnaround time, and cost-effectiveness, while providing ample cellular material for diagnostic and therapeutic studies. The implementation of this WHO system promotes uniformity and reproducibility in cytological diagnoses and enhances risk stratification based on cytopathologic findings. A critical aspect of its success is recognizing the potential pitfalls of fine-needle aspiration biopsy interpretation, including sampling errors and diagnostic challenges, particularly in lymphoma cases. The active participation of hematopathologists, hematologists, and oncologists will be essential for refining and widely adopting this system. Further multicentric studies with diverse epidemiological cohorts and larger sample sizes will be instrumental in validating its clinical utility and ensuring its integration into routine practice.

The recently introduced WHO Reporting System for Soft Tissue Cytopathology, reviewed by Marilyn M. Bui, represents a significant advancement in the classification of soft tissue neoplasms.[7] This system categorizes soft tissue lesions into six diagnostic groups: Non-Diagnostic, Benign, Atypical, Soft Tissue Neoplasms of Uncertain Malignant Potential, Suspicious for Malignancy, and Malignant. The structured classification enhances risk assessment, improves communication among pathologists and clinicians, and facilitates more consistent diagnosis and treatment strategies. The integration of molecular diagnostics and immunocytochemistry in soft tissue cytopathology aligns with the broader trend of incorporating ancillary testing into modern reporting systems, ultimately refining diagnostic accuracy and patient management.

As new WHO-IAC systems for liver, breast, kidney and adrenal, and head and neck cytopathology emerge, they will further contribute to a harmonized, globally applicable framework for cytopathologic diagnoses. The ongoing expansion of these systems reflects the need for a comprehensive, evidence-based approach to cytopathology reporting, ensuring that pathologists worldwide have access to standardized tools that enhance diagnostic precision and improve patient outcomes.

Collectively, the articles in this special issue highlight the transformative role of structured reporting in cytopathology. While each system addresses a specific anatomical site, they share common goals: improving diagnostic precision, minimizing interobserver variability, and optimizing patient management. The integration of molecular testing into these systems represents the next frontier, offering enhanced risk assessment and personalized treatment options.[21] As cytopathology continues to evolve, future efforts should focus on refining reporting criteria, integrating artificial intelligence and digital pathology, and expanding the use of ancillary molecular tests. The ongoing development and adoption of these structured reporting systems will undoubtedly contribute to improved diagnostic accuracy and better patient outcomes worldwide. While these reporting systems have transformed practice, their implementation faces challenges, including variable adoption in resource-limited settings and the need for continuous updates to incorporate molecular diagnostics, highlighting the importance of international collaboration and training initiatives.

We hope that this special issue serves as a valuable resource for cytopathologists, clinicians, and researchers, fostering further advancements in the field and reinforcing the essential role of standardized reporting in modern pathology.

Conflict of interest

Dr. Schmitt has been an editorial board member of the *Journal of Clinical and Translational Pathology* since May 2023.

Author contributions

FS is the sole author of this editorial.

References

[1] Field AS, Pitman M, Cree IA, Canberk S, Bubendorf L, Mahrotra R, *et al*. The rationale for the development and publication of the World Health Organization reporting systems for cytopathology and a brief overview of the first editions of the lung and pancreaticobiliary systems. Cancer Cytopathol 2023;131(12):751–761. doi:10.1002/cncy.22757, PMID:37702127.

[2] Schmitt FC, Bubendorf L, Canberk S, Chandra A, Cree IA, Engels M, *et al*. The World Health Organization Reporting System for Lung Cytopathology. Acta Cytol 2023;67(1):80–91. doi:10.1159/000527580, PMID: 36509066.

[3] Dolezal D, Kholová I, Cai G. The World Health Organization Reporting System for Lung Cytopathology-A Review of the First Edition. J Clin Transl Pathol 2024;4(1):18–35. doi:10.14218/jctp.2023.0068, PMID:38736711.

[4] Pitman MB, Centeno BA, Reid MD, Siddiqui MT, Layfield LJ, Perez-Machado M, *et al*. The World Health Organization Reporting System for Pancreaticobiliary Cytopathology. Acta Cytol 2023;67(3):304–320. doi:10.1159/000527912, PMID:36516741.

[5] Wang M, Lozano MD, Cai G. The World Health Organization System for Reporting Pancreaticobiliary Cytopathology: Standardized Categories and Practical Approaches to Pancreatic Lesions. J Clin Transl Pathol 2024; 4(3):122–135. doi:10.14218/jctp.2024.00034, PMID:40191142.

[6]   Gao Y, Monaco SE, Katz RL, Zhang YH. Introduction of the WHO Reporting System for Lymph Node Cytopathology. J Clin Transl Pathol 2024;4(1):36–43. doi:10.14218/JCTP.2023.00044.

[7]   Bui M. World Health Organization Reporting System for Soft Tissue Cytopathology: A Concise Review with a Practical Diagnostic Approach. J Clin Transl Pathol 2025. doi:10.14218/JCTP.2025.00016.

[8]   Wang T, Zhang H, Liu Y, Zhao C. Updates in Cervical Cancer Screening Guidelines, The Bethesda System for Reporting Cervical Cytology, and Clinical Management Recommendations. J Clin Transl Pathol 2023;3(2):75–83. doi:10.14218/jctp.2023.00004, PMID:37456763.

[9]   Han M, Fan F. Bethesda System for Reporting Thyroid Cytopathology–An Updated Review. J Clin Transl Pathol 2023;3(2):84–98. doi:10.14218/JCTP.2023.00005.

[10] Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA. The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2023;33(9):1039–1044. doi:10.1089/thy.2023.0141, PMID:37427847.

[11] Wojcik EM, Kurtycz DF, Rosenthal DL, editors. The Paris System for Reporting Urinary Cytology. 2nd ed. Cham: Springer; 2022. doi:10.1007/978-3-030-88686-8.

[12] Chen F, Lin X. The Paris System for Reporting Urinary Cytology: An Updated Review. J Clin Transl Pathol 2023;3(2):59–74. doi:10.14218/JCTP.2022.00035.

[13] Field AS, Raymond WA, Schmitt FC. The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology. Acta Cytol 2019;63(4):255–256. doi:10.1159/000501055, PMID:31137023.

[14] Yu W, Gan Q, Gong Y. The Yokohama System for Reporting Breast Cytopathology. J Clin Transl Pathol 2023;3(2):99–105. doi:10.14218/JCTP.2023.00006.

[15] Montezuma D, Malheiros D, Schmitt FC. Breast Fine Needle Aspiration Biopsy Cytology Using the Newly Proposed IAC Yokohama System for Reporting Breast Cytopathology: The Experience of a Single Institution. Acta Cytol 2019;63(4):274–279. doi:10.1159/000492638, PMID:30783035.

[16] Wang X, Wang H. The Milan System for Reporting Salivary Gland Cytopathology and Updates. J Clin Transl Pathol 2023;3(3):126–133. doi:10.14218/JCTP.2023.00011.

[17] Bishop JA. Immunohistochemistry surrogates for molecular alterations: A new paradigm in salivary gland tumor cytopathology? Cancer Cytopathol 2021;129(2):102–103. doi:10.1002/cncy.22337, PMID:32809250.

[18] Wang M, Chandra A, Cai G. The International System for Reporting Serous Fluid Cytopathology-An Updated Review. J Clin Transl Pathol 2023;3(4):160–177. doi:10.14218/jctp.2023.00025, PMID:39372684.

[19] Pinto D, Cruz E, Branco D, Linares C, Carvalho C, Silva A, et al. Cyto-histological Correlation in Pleural Effusions Based on the International System for Reporting Serous Fluid Cytopathology. Diagnostics (Basel) 2021;11(6):1126. doi:10.3390/diagnostics11061126, PMID:34203073.

[20] Chandra A, Crothers B, Kurtycz D, Schmitt F, editors. The International System for Serous Fluid Cytopathology. Cham: Springer; 2020 . doi:10.1007/978-3-030-53908-5.

[21] Silva RSD, Schmitt F. Next step of molecular pathology: next-generation sequencing in cytology. J Pathol Transl Med 2024;58(6):291–298. doi:10.4132/jptm.2024.10.22, PMID:39557410.